Patents by Inventor Peter Boross

Peter Boross has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES CAPABLE OF BINDING TO CD27, VARIANTS THEREOF AND USES THEREOF
    Publication number: 20230212301
    Abstract: The present invention relates to antibodies capable of binding to human CD27 and to variants thereof comprising a modified Fc region comprising one or more mutations that enhances the Fc-Fc interaction of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Application
    Filed: November 14, 2022
    Publication date: July 6, 2023
    Inventors: Andreea Ioan, Frank Beurskens, Rob N. de Jong, Janine Schuurman, Esther C. W. Breij, Isil Altintas, Pauline L. de Goeje, David Satijn, Peter Boross, Ugur Sahin, Friederike Gieseke, Alexander Muik, Kristina Schödel
  • ANTIBODIES CAPABLE OF BINDING TO CD27, VARIANTS THEREOF AND USES THEREOF
    Publication number: 20230109496
    Abstract: The present invention relates to antibodies capable of binding to human CD27 and to variants thereof comprising a modified Fc region comprising one or more mutations that enhances the Fc-Fc interaction of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Application
    Filed: September 6, 2022
    Publication date: April 6, 2023
    Inventors: Andreea Ioan, Frank Beurskens, Rob N. de Jong, Janine Schuurman, Esther C. W. Breij, Isil Altintas, Pauline L. de Goeje, David Satijn, Peter Boross, Ugur Sahin, Friederike Gieseke, Alexander Muik, Kristina Schödel
  • ENGINEERED ANTIBODIES AND METHODS OF TREATMENT
    Publication number: 20230022731
    Abstract: The invention is related to CD20 antibodies with improved characteristics. Some embodiments describe antibodies comprising a mouse IgG2; a human IgG1, IgA1 or IgA2 constant region and a variable domain that can bind the epitope “EPANpSEK” on human CD20 expressed on Ramos cells and which antibody has an increased PCD functionality when compared to Rituximab with a constant region of the same isotype.
    Type: Application
    Filed: June 15, 2022
    Publication date: January 26, 2023
    Inventors: Jeannette Henrica Wilhelmina LEUSEN, Peter BOROSS, Johannes Hendrik Marco JANSEN, Saskia MEYER
  • CD20 antibodies
    Patent number: 11414495
    Abstract: CD20 antibodies with improved characteristics. Some embodiments describe antibodies comprising a mouse IgG2; a human IgG1, IgA1 or IgA2 constant region and a variable domain that can bind the epitope “EPANpSEK” (SEQ ID NO:31) on human CD20 expressed on Ramos cells and which antibody has an increased PCD functionality when compared to Rituximab with a constant region of the same isotype.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: August 16, 2022
    Assignee: TIGA TX, INC.
    Inventors: Jeannette Henrica Wilhelmina Leusen, Peter Boross, Johannes Hendrik Marco Jansen, Saskia Meyer
  • Monoclonal antibodies against the active site of factor XI and uses thereof
    Patent number: 11059905
    Abstract: The present invention provides novel anti-factor XI (FXI) antibodies and compositions comprising such antibodies. The anti-FXI antibodies of the invention specifically bind to the active center of FXI and inhibit the functional activity of FXI. The invention further provides humanized versions of the anti-FXI antibodies that are useful in the prevention and treatment of conditions in which pathological thrombus formation or thrombo-embolism are involved. The invention further provides nucleic acid molecules encoding the anti-FXI antibodies, cells expressing the anti-FXI antibodies and methods for producing the anti-FXI antibodies.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: July 13, 2021
    Assignee: Prothix B.V.
    Inventors: Péter Boross, Cafer Yildiz, Cornelis Erik Hack
  • CD20 ANTIBODIES
    Publication number: 20190263922
    Abstract: The invention is related to CD20 antibodies with improved characteristics. Some embodiments describe antibodies comprising a mouse IgG2; a human IgG1, IgA1 or IgA2 constant region and a variable domain that can bind the epitope “EPANpSEK” on human CD20 expressed on Ramos cells and which antibody has an increased PCD functionality when compared to Rituximab with a constant region of the same isotype.
    Type: Application
    Filed: September 1, 2017
    Publication date: August 29, 2019
    Inventors: Jeanette Henrica Wilhelmina Leusen, Peter Boross, Johannes Hendrik Marco Jansen, Saskia Meyer
  • Monoclonal antibodies against the active site of factor XI and uses thereof
    Publication number: 20190106509
    Abstract: The present invention provides novel anti-factor XI (FXI) antibodies and compositions comprising such antibodies. The anti-FXI antibodies of the invention specifically bind to the active center of FXI and inhibit the functional activity of FXI. The invention further provides humanized versions of the anti-FXI antibodies that are useful in the prevention and treatment of conditions in which pathological thrombus formation or thrombo-embolism are involved. The invention further provides nucleic acid molecules encoding the anti-FXI antibodies, cells expressing the anti-FXI antibodies and methods for producing the anti-FXI antibodies.
    Type: Application
    Filed: March 23, 2017
    Publication date: April 11, 2019
    Applicant: Prothix B.V.
    Inventors: Péter Boross, Cafer Yildiz, Cornelis Erik Hack